A hydrate of dimethylaminomicheliolide fumarate has a crystal form D, is high in crystallinity, smooth in particle surface, free of coalescence, high in bulk density and good in flowability, and has good stability and good reproducibility. Its preparation method includes: under a stirring action, adding dimethylamine micheliolide and fumaric acid into a mixed solvent system having a constant temperature of 30° C.-70° C. for reaction crystallization; and filtering after the reaction is finished, and drying filtered solid at normal pressure to obtain the crystal form D of the dimethylaminomicheliolide fumarate.

Metal Organic Framework (MOF) materials and methods of making MOF materials. The methods include grinding of mixtures of metal hydroxide(s) and ligand(s). The MOF materials may have at least two different ligands. The MOF materials may have open metal sites. The MOF materials can be used in gas storage applications.

Metal Organic Framework (MOF) materials and methods of making MOF materials. The methods include grinding of mixtures of metal hydroxide(s) and ligand(s). The MOF materials may have at least two different ligands. The MOF materials may have open metal sites. The MOF materials can be used in gas storage applications.

The disclosure relates to crystalline forms of bis(4-hydroxy-N-methyl-N-isopropyltryptannnonium) fumarate (“crystalline bis-miprocin fumarate”), compositions containing that crystalline form, and their methods of treatment using them.

This disclosure relates to crystalline bis(4-hydroxy-N,N-d-n-propyltryptammonium)fumarate tetrahydrate (4-HO-DPT fumarate-4H.sub.2O) and to Crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride (4-HO-DPT chloride). Compositions containing crystalline 4-HO-DPT fumarate-4H.sub.2O or crystalline 4-HO-DPT chloride, and methods of use are disclosed.

Metal-organic frameworks (MOFs) may have Zn(II), Pb(II), and/or Cd(II) as a central metal ion; a 4,4′-bipyridylethylene (bpe) ligand as a first ligand; and fumaric acid (fum) and/or oxalic acid (ox) as a second ligand, wherein the 4,4′-bipyridylethylene ligands are stacked in the MOF, and wherein a distance between two consecutive 4,4′-bipyridylethylene ligands is less than 5 Å. Cycloadditions, particularly photoinduced [2+2] cycloadditions may be catalyzed by such MOFs, and/or the conversion of photoinduced [2+2] cycloadditions in inventive MOFs may be increased by mechanical force, such as by grinding.

Metal-organic frameworks (MOFs) may have Zn(II), Pb(II), and/or Cd(II) as a central metal ion; a 4,4′-bipyridylethylene (bpe) ligand as a first ligand; and fumaric acid (fum) and/or oxalic acid (ox) as a second ligand, wherein the 4,4′-bipyridylethylene ligands are stacked in the MOF, and wherein a distance between two consecutive 4,4′-bipyridylethylene ligands is less than 5 Å. Cycloadditions, particularly photoinduced [2+2] cycloadditions may be catalyzed by such MOFs, and/or the conversion of photoinduced [2+2] cycloadditions in inventive MOFs may be increased by mechanical force, such as by grinding.

The disclosure relates to 5-methoxy-N,N-diallyltryptamine (“5-MeO-DALT”), bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), and crystalline bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), compositions containing them, and the methods of treatment using them.

A benzodiazepine compound represented by formula I, or a salt thereof has an intravenous sedative anesthesia effect. The recovery quality of the compound is significantly improved compared with remimazolam in rat and mouse caudal venous anesthesia models. During anesthetization, the compound has a rapid onset, a short duration, a quick recovery and a good tolerance, can be used for anesthesia induction, anesthesia maintenance and day surgery anesthesia.

##STR00001##

The present invention relates generally to the field of pharmaceuticals, and specifically relates to isofagomine (IFG), novel salts thereof and preparation methods and uses of these, for example, in formulating pharmaceutical compositions for the treatment of Gaucher disease. Also provided are novel crystalline forms of isofagomine salts, methods for preparing the crystalline forms, and their use in formulating pharmaceutical compositions.